Clinical trial
Efficacy and Tolerability of Novel A2A Agonist in Treatment of Diabetic…
NCT00452777 · Swedish Orphan Biovitrum, Industry · Completed
Key facts
| NCT number | NCT00452777 |
|---|---|
| Title | Efficacy and Tolerability of Novel A2A Agonist in Treatment of Diabetic Neuropathic Pain |
| Official title | A Double-blind, Placebo-controlled, Randomized, Parallel-group Study Evaluating the Efficacy and Tolerability of Oral BVT.115959, a Novel A2A Agonist, Versus Placebo in the Treatment of Diabetic Neuropathic Pain |
| Lead sponsor | Swedish Orphan Biovitrum, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Diabetic Neuropathic Pain |
| Intervention type | Drug |
| Interventions | BVT.115959, Placebo |
| Enrollment | 193 |
| Start date | May 1, 2007 |
| Primary completion | Dec 1, 2007 |
| Completion | Jan 1, 2008 |
| First posted | Mar 27, 2007 |
| Last update posted | Nov 3, 2014 |
| Countries | Czechia, Germany, South Africa |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: